AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35704616 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 242
Study 35704616 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 242
Study 32954994 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive perceptions of procedural justice
Number of subjects: 571
Study 32954994 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim alcohol consumption
Number of subjects: 571
Study 32954994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rape myth acceptance
Number of subjects: 571
Study 32954994 — intervention group
Group type: COMPARATOR
Intervention: Victim race
Number of subjects: 571
Study 32954994 — intervention group
Group type: COMPARATOR
Intervention: Participant sex
Number of subjects: 571
Study 32224333 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 24
Study 32224333 — intervention group
Group type: COMPARATOR
Intervention: Sham attention tasks (Control)
Number of subjects: 24
Study 36096354 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry
Number of subjects: 135
Study 36096354 — intervention group
Group type: EXPERIMENTAL
Intervention: Icare rebound tonometry
Number of subjects: 135
Study 36096354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatonometry
Number of subjects: 135
Study 36096354 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebound tonometry
Number of subjects: 135
Study 36096354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumotonometry
Number of subjects: 135
Study 35038956 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band intense pulsed light (DPL) treatment at a wavelength of 500-600 nm, initiated 2 weeks post-surgery, given 3 times over a 4-week period.
Number of subjects: 9
Study 35038956 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated half of the scar)
Number of subjects: 9
Study 32505193 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training alone
Number of subjects: 13
Study 32505193 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training + high-protein diet
Number of subjects: 13
Study 32505193 — intervention group
Group type: COMPARATOR
Intervention: Control (free diet, no exercise)
Number of subjects: 13
Study 36355827 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga intervention self-administered over six weeks using an audio recording file
Number of subjects: 50
Study 36355827 — intervention group
Group type: COMPARATOR
Intervention: Usual care education (Control group)
Number of subjects: 50
Study 36355827 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga intervention
Number of subjects: 50
Study 32544846 — intervention group
Group type: EXPERIMENTAL
Intervention: High fructose meal challenge
Number of subjects: 46
Study 32544846 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucose meal challenge
Number of subjects: 46
Study 32544846 — intervention group
Group type: EXPERIMENTAL
Intervention: Average glucose meal challenge
Number of subjects: 46
Study 33871234 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT (Chains Resistance Training)
Number of subjects: 30
Study 33871234 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT (Traditional Resistance Training)
Number of subjects: 30
Study 33871234 — intervention group
Group type: COMPARATOR
Intervention: CG (Control Group)
Number of subjects: 30
Study 33992718 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-WBI (50 Gray [Gy]/25 fractions plus boost)
Number of subjects: 287
Study 33992718 — intervention group
Group type: COMPARATOR
Intervention: HF-WBI (42.56 Gy/16 fractions plus boost)
Number of subjects: 287
Study 33992718 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-WBI and HF-WBI
Number of subjects: 287
Study 33992718 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-WBI
Number of subjects: 287
Study 33992718 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-WBI
Number of subjects: 287
Study 32487944 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure Intervention Trial (subset of patients with CKD)
Number of subjects: 0
Study 32487944 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure in Dialysis Trial (pilot study)
Number of subjects: 0
Study 35589026 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention using data-driven methods and training in interactive workshops
Number of subjects: 0
Study 35589026 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 0
Study 33737437 — intervention group
Group type: EXPERIMENTAL
Intervention: upfront autologous HSCT
Number of subjects: 120
Study 33737437 — intervention group
Group type: COMPARATOR
Intervention: immunosuppressive therapy (intravenous cyclophosphamide pulse therapy followed by mycophenolate mofetil) with rescue HSCT in case of treatment failure
Number of subjects: 120
Study 32989958 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 32989958 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen and aromatase inhibitors
Number of subjects: 0
Study 35802065 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention
Number of subjects: 118
Study 35802065 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 118
Study 32471423 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg via Ellipta inhaler
Number of subjects: 720
Study 32471423 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily budesonide/formoterol (BUD/FOR) 400/12 μg via metered-dose inhaler plus once-daily tiotropium (TIO) 18 μg via HandiHaler
Number of subjects: 720
Study 32471423 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily budesonide/formoterol (BUD/FOR) 400/12 μg plus once-daily tiotropium (TIO) 18 μg via HandiHaler
Number of subjects: 720
Study 616734690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner victimization
Number of subjects: 1233
Study 616734690 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risk behaviors
Number of subjects: 1233
Study 34838606 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 2 weeks
Number of subjects: 474
Study 33354757 — intervention group
Group type: EXPERIMENTAL
Intervention: Men dissatisfied with their sex life
Number of subjects: 6048
Study 33354757 — intervention group
Group type: EXPERIMENTAL
Intervention: Men reporting having had less sex than they would have liked
Number of subjects: 6048
Study 33354757 — intervention group
Group type: EXPERIMENTAL
Intervention: Men who have looked for or met sex partners online
Number of subjects: 6048
Study 33354757 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent pornography users
Number of subjects: 6048
Study 33658645 — intervention group
Group type: EXPERIMENTAL
Intervention: R-DHAOx (oxaliplatin)
Number of subjects: 298
Study 33658645 — intervention group
Group type: COMPARATOR
Intervention: R-DHACis (cisplatin) or R-DHACa (carboplatin)
Number of subjects: 298
Study 33060088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghost ileostomy
Number of subjects: 60
Study 33060088 — intervention group
Group type: COMPARATOR
Intervention: Conventional loop ileostomy
Number of subjects: 60
Study 32475229 — intervention group
Group type: EXPERIMENTAL
Intervention: Two needles arthrocentesis (TNA)
Number of subjects: 20
Study 32475229 — intervention group
Group type: COMPARATOR
Intervention: Double-needle cannula arthrocentesis (DNCA)
Number of subjects: 20
Study 34734811 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization during primary PCI (PPCI)
Number of subjects: 100
Study 34734811 — intervention group
Group type: COMPARATOR
Intervention: Complete revascularization during the same hospital admission
Number of subjects: 100
Study 35822553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg once per day for 6 months
Number of subjects: 30
Study 35822553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33045224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily (15 mg for creatinine clearance <50 mL/min)
Number of subjects: 1005
Study 33045224 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted warfarin (target INR 2.0-3.0)
Number of subjects: 1005
Study 33045224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1005
Study 33045224 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1005
Study 35449839 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency nerve therapy device
Number of subjects: 140
Study 35449839 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment methods (Control)
Number of subjects: 140
Study 33059519 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) for four weeks (20 min/3 days/week)
Number of subjects: 32
Study 33059519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EMS intervention)
Number of subjects: 32
Study 32471397 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Restraint Systems (CRS) use among children aged 0-5
Number of subjects: 9858
Study 32471397 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Restraint Systems (CRS) use among children aged 6-11
Number of subjects: 9858
Study 32471397 — intervention group
Group type: COMPARATOR
Intervention: Sitting in the front row for children aged 0-11
Number of subjects: 9858
Study 32471397 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting in the rear row with CRS use for children aged 0-11
Number of subjects: 9858
Study 32471397 — intervention group
Group type: EXPERIMENTAL
Intervention: Seat belt use among children aged 12-17
Number of subjects: 9858
Study 35460702 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV‐NAVA
Number of subjects: 78
Study 35460702 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 78
Study 33728932 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL-C
Number of subjects: 4199
Study 33728932 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic dyslipidemia
Number of subjects: 4199
Study 32703188 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection dogs trained to identify SARS-CoV-2 infected samples
Number of subjects: 8
Study 32703188 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-infected samples)
Number of subjects: 8
Study 35575280 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepare to Care intervention
Number of subjects: 38
Study 35575280 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 38
Study 32122870 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg tablet b.i.d and enzyme supplements 250 mg b.i.d for 6 weeks
Number of subjects: 40
Study 32122870 — intervention group
Group type: COMPARATOR
Intervention: Aceclofenac 100 mg tablet b.i.d
Number of subjects: 40
Study 35304704 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency defined as soluble transferrin receptor (sTfR) > 28.1 nmol/L
Number of subjects: 2157
Study 35304704 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency defined as ferritin < 45 µg/L
Number of subjects: 2157
Study 35304704 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency defined as ferritin < 30 µg/L
Number of subjects: 2157
Study 35304704 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency defined as sTfR-ferritin index > 1.5
Number of subjects: 2157
Study 35304704 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rate (IR) of iron deficiency per 100 person-years
Number of subjects: 2157
Study 35304704 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rate (IR) for ferritin < 45 µg/L
Number of subjects: 2157
Study 35304704 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rate (IR) for ferritin < 30 µg/L
Number of subjects: 2157
Study 35304704 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rate (IR) for sTfR-ferritin index > 1.5
Number of subjects: 2157
Study 33442660 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry-3 surrogate classifier
Number of subjects: 798
Study 33442660 — intervention group
Group type: EXPERIMENTAL
Intervention: St. Gallen surrogate classifier
Number of subjects: 798
Study 33442660 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolif surrogate classifier
Number of subjects: 798
Study 33442660 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 subtyping
Number of subjects: 798
Study 33442660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment benefit
Number of subjects: 798
Study 32282418 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP‐XR (300 mg initial injection, followed by monthly doses of 300 mg or 100 mg)
Number of subjects: 669
Study 35276451 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised task-oriented circuit training (TOCT) followed by a home-based task-oriented program
Number of subjects: 36
Study 33323434 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine measurement and reporting of EuroQoL 5‐Dimension 5‐Level (EQ‐5D‐5L) HRQOL data using an electronic platform
Number of subjects: 0
Study 33323434 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study 33323434 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), 10-point Pain Rating Scale, and structured questionnaire
Number of subjects: 0
Study 36411585 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked Colour Imaging (LCI)
Number of subjects: 1828
Study 36411585 — intervention group
Group type: COMPARATOR
Intervention: White Light Imaging (WLI)
Number of subjects: 1828
Study 32434372 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month low-calorie diet (LCD)
Number of subjects: 96
Study 32434372 — intervention group
Group type: COMPARATOR
Intervention: Ordinary diet (control)
Number of subjects: 96
Study 35510087 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (up to 400 mg per day)
Number of subjects: 29
Study 35510087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 33774680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bright light during work (N=14)
Number of subjects: 29
Study 33774680 — intervention group
Group type: COMPARATOR
Intervention: Indoor light (Control group, N=15)
Number of subjects: 29
Study 32270440 — intervention group
Group type: EXPERIMENTAL
Intervention: Imeglimin (IMEG) 1500 mg twice daily with Metformin (MET) 850 mg twice daily
Number of subjects: 32
Study 32270440 — intervention group
Group type: EXPERIMENTAL
Intervention: Imeglimin (IMEG) 1500 mg twice daily with Sitagliptin (SITA) 100 mg once daily
Number of subjects: 32
Study 32270440 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET) 850 mg twice daily with placebo
Number of subjects: 32
Study 32270440 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (SITA) 100 mg once daily with placebo
Number of subjects: 32
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2614
Study 35778856 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation
Number of subjects: 2614
Study 35782072 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial artery chemoembolization (BACE) combined with 125I seed implantation
Number of subjects: 102
Study 35782072 — intervention group
Group type: COMPARATOR
Intervention: 125I seed implantation
Number of subjects: 102
Study 34152584 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab biosimilar PF-05280586 (RTX-PF)
Number of subjects: 394
Study 34152584 — intervention group
Group type: COMPARATOR
Intervention: Reference rituximab sourced from the EU (RTX-EU)
Number of subjects: 394
Study 33028147 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 15
Study 33028147 — intervention group
Group type: EXPERIMENTAL
Intervention: Levcromakalim
Number of subjects: 15
Study 33028147 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide with Levcromakalim
Number of subjects: 15
Study 35470909 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3, 600,000 IU 5 days before surgery (Group B)
Number of subjects: 196
Study 35470909 — intervention group
Group type: COMPARATOR
Intervention: General standard of care (Group A)
Number of subjects: 196
Study 33982986 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA® Gastro™ airway
Number of subjects: 103
Study 33982986 — intervention group
Group type: COMPARATOR
Intervention: gastrolaryngeal tube (GLT)
Number of subjects: 103
Study 32861830 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational film on chronic viral hepatitis (CVH)
Number of subjects: 219
Study 32861830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-intervention questionnaire
Number of subjects: 219
Study 32861830 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention questionnaire
Number of subjects: 219
Study 35314325 — intervention group
Group type: EXPERIMENTAL
Intervention: Glassia (60 mg/kg body weight, weekly intravenous administration)
Number of subjects: 50
Study 35314325 — intervention group
Group type: COMPARATOR
Intervention: Prolastin (control group)
Number of subjects: 50
Study 33179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline)
Number of subjects: 1088
Study 33179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (675 mg at baseline; 225 mg at Weeks 4 and 8)
Number of subjects: 1088
Study 33179323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study 35677368 — intervention group
Group type: EXPERIMENTAL
Intervention: Squill-Oxymel
Number of subjects: 42
Study 35677368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 32273630 — intervention group
Group type: EXPERIMENTAL
Intervention: Abound (24 g) administered for 14 days through an enteral feeding tube
Number of subjects: 10
Study 32273630 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (20 patients)
Number of subjects: 10
Study 34555204 — intervention group
Group type: EXPERIMENTAL
Intervention: ATB‐346
Number of subjects: 0
Study 34555204 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study 34555204 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study 32583478 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Cognitive‐Affective Therapy (ICAT‐BED)
Number of subjects: 112
Study 32583478 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐Behavioral Guided Self‐Help (CBTgsh)
Number of subjects: 112
Study 36434858 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 100-129
Number of subjects: 103
Study 36434858 — intervention group
Group type: COMPARATOR
Intervention: SBP 130-160
Number of subjects: 103
Study 36434858 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 100-129 with BBB disruption
Number of subjects: 103
Study 36434858 — intervention group
Group type: COMPARATOR
Intervention: SBP 130-160 with BBB disruption
Number of subjects: 103
Study 32896932 — intervention group
Group type: EXPERIMENTAL
Intervention: QS-755 nm
Number of subjects: 41
Study 32896932 — intervention group
Group type: EXPERIMENTAL
Intervention: QS-532 nm
Number of subjects: 41
Study 32896932 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-755 nm
Number of subjects: 41
Study 32896932 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment satisfaction
Number of subjects: 41
Study 32503867 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based digital stewardship applications (apps) with local guideline directed empirical antimicrobial use by physicians
Number of subjects: 540
Study 32503867 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based digital stewardship applications (apps)
Number of subjects: 540
Study 32503867 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the app by everyone after the intervention period
Number of subjects: 540
Study 35098531 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) N-acetylcysteine (NAC) in healthy volunteers with contrast
Number of subjects: 66
Study 35098531 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) NAC in healthy volunteers without contrast
Number of subjects: 66
Study 35098531 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) NAC in patients with CKD3 receiving contrast
Number of subjects: 66
Study 35098531 — intervention group
Group type: COMPARATOR
Intervention: Oral NAC in healthy volunteers
Number of subjects: 66
Study 35098531 — intervention group
Group type: COMPARATOR
Intervention: Oral NAC in patients with CKD3
Number of subjects: 66
Study 35098531 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) NAC in patients with CKD3 without contrast
Number of subjects: 66
Study 33004272 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 87
Study 33004272 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX
Number of subjects: 87
Study 33004272 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin treatment < 2 months prior to EVA/PCD analysis
Number of subjects: 87
Study 33004272 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU
Number of subjects: 87
Study 33004272 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin and Irinotecan
Number of subjects: 87
Study 33974993 — intervention group
Group type: EXPERIMENTAL
Intervention: LCS restriction (replacement of diet beverages with still or sparkling water and avoidance of other sources of LCSs)
Number of subjects: 0
Study 33974993 — intervention group
Group type: COMPARATOR
Intervention: Usual LCS intake (control)
Number of subjects: 0
Study 33415870 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion group
Number of subjects: 90
Study 33415870 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal cake separated moxibustion group
Number of subjects: 90
Study 33415870 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation group
Number of subjects: 90
Study 36235821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB) consumption with glucose
Number of subjects: 0
Study 36235821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB) consumption with fructose
Number of subjects: 0